Pharmaceuticals

Global Cancer Immunotherapy Drug Discovery Outsourcing Market Projected to Reach $2.45 Billion by 2029 at a CAGR of 10.2%

August 22, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Current and Projected Market Size of the Cancer Immunotherapy Drug Discovery Outsourcing Market Through 2034?#_x000D_

The market for outsourcing cancer immunotherapy drug discovery has experienced substantial growth in the past few years. The market, which was valued at $1.5 billion in 2024, is projected to expand to $1.66 billion in 2025, with a compound annual growth rate (CAGR) of 10.6%. The surge during the historical period is mainly due to the rise in adverse drug reaction cases, augmented demand for all-inclusive genomic testing, a growing worldwide prevalence of cancer, the increasing necessity for targeted therapies, and the burgeoning number of clinical trials._x000D_

_x000D_

The market for outsourcing the discovery of cancer immunotherapy drugs is anticipated to experience swift expansion in the coming years. The market is set to reach $2.45 billion in 2029, with a compound annual growth rate (CAGR) of 10.2%. This prospective growth during the forecast period is due to factors such as the growing significance of personalized medicine, an increase in diagnostic tests, a heightened focus on personalized cancer treatment, elevated healthcare spending, and enhanced awareness and occurrence of cancer. Noteworthy trends throughout this period consist of advancements in diagnostic technologies and next-generation sequencing (NGS), the integration of artificial intelligence (AI), advancements in liquid biopsy technologies, the creation of point-of-care companion diagnostic devices, and the emergence of innovative testing technologies._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=15528&type=smp_x000D_

_x000D_

#What are the Fundamental Drivers and Innovations Shaping the Cancer Immunotherapy Drug Discovery Outsourcing Market?#_x000D_

The growth of the cancer immunotherapy drug discovery outsourcing market is anticipated to be fueled by the considerable costs associated with research and development. These high expenses derive mainly from the necessity for specialist knowledge, high-priced apparatus, and the inherent uncertainties associated with innovation. The practice of outsourcing drug discovery work makes use of the scale economies provided by contract research organizations (CROs). This allows smaller biotechnological companies and new ventures to better optimize their R&D budgets and distribute resources in a more cost-effective way. As an illustration, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that in June 2023, the total R&D expenditure in the pharmaceutical sector in Europe amounted to $49,500 million (€44,500 million) in 2022, reflecting an estimated increase of 6.45% from $46,500 million (€42,533 million) in 2021. Thus, the substantial costs for conducting in-house research and development are spurring the expansion of the cancer immunotherapy drug discovery outsourcing market._x000D_

_x000D_

#How Is the Cancer Immunotherapy Drug Discovery Outsourcing Market Segmented?#_x000D_

The cancer immunotherapy drug discovery outsourcing market covered in this report is segmented – _x000D_

_x000D_

1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies And Cancer Vaccines, Other Drug Types_x000D_

2) By Service Type: Target Identification And Validation, Lead Screening And Characterization, Cell-Based Assays_x000D_

3) By Therapeutic Area: Lung Cancer, Breast Cancer, Melanoma, Other Therapeutic Areas_x000D_

_x000D_

Subsegments:_x000D_

1) By Monoclonal Antibodies: Checkpoint Inhibitors, Therapeutic Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs) _x000D_

2) By Immunomodulators: Cytokines, Immune Checkpoint Modulators, Toll-Like Receptor Agonists, Immune Adjuvants _x000D_

3) By Oncolytic Viral Therapies And Cancer Vaccines: Oncolytic Virus-Based Therapies, Cancer Vaccines, Viral Vectors For Immunotherapy _x000D_

4) By Other Drug Types: Adoptive Cell Therapy, Immune Cell Modulators, Small Molecule Immune Modulators, Gene Editing And Immunotherapy_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=15528&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Cancer Immunotherapy Drug Discovery Outsourcing Market Growth?#_x000D_

North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Trends Are Shaping the Future of the Cancer Immunotherapy Drug Discovery Outsourcing Market?#_x000D_

Large corporations in the cancer immunotherapy drug discovery outsourcing market are leveraging strategic partnerships to bolster their cancer drug production and secure a competitive edge. Strategic partnerships generally encompass collaborative alliances between multiple organizations, pooling their resources, knowledge, and endeavors towards shared aims or goals. For example, in February 2022, Ono Pharmaceutical Co., Ltd., a pharmaceutical firm based in Japan, and Bristol-Myers Squibb, a biopharmaceutical company based in the US, agreed to an outsourcing deal with the Prime Research Institute for Medical Research, Inc., a Japanese research institution, for a joint clinical research project centered on stomach cancer patients undergoing treatment with Opdivo (nivolumab) and chemotherapy. This industry-backed initiative features a comprehensive, multi-institution study deployed through PRiME-R’s data input assistance system known as CyberOncology, which aids in the standardization, arrangement, supervision, and amalgamation of real-world data in standard cancer clinic settings. This clinical research, with CyberOncology’s aid, assesses Opdivo in conjunction with chemotherapy for treating advanced or relapsed stomach cancer. It enlists approximately 30 medical establishments on a national scale with the objective to refine data input, improve data precision, and accelerate analysis._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-drug-discovery-outsourcing-global-market-report_x000D_

_x000D_

#How Is the Cancer Immunotherapy Drug Discovery Outsourcing Market Defined and What Are Its Core Parameters?#_x000D_

Cancer immunotherapy drug discovery outsourcing is a specialized service model in the pharmaceutical and biotech sectors. It entails delegating aspects of cancer immunotherapy drug development to external service providers, typically contract research organizations (CROs) or contract development and manufacturing organizations (CDMOs) to speeds up innovation by leveraging external expertise and resources, letting pharmaceutical companies focus on core activities._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15528_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_